The development of these and additional KO tumor models will also allow exploring the potential of novel treatements beyond ICB, such as IL-15 and IL-12 immunocytokine therapies, where the presence of these tumor-cell intrinsic gene defects may add clinical benefit via NK cells. The gene discussed is IL15; the disease is neoplasm.